AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00035932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir + tenofovir + nucleoside
Description: Active Comparator, Capsules, tablets, Oral
Study NCT01780220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone acetate 1000mg/day + prednisone alone for one month before initiating the sequence of radiotherapy
Study NCT04292418 — intervention group
Intervention type: DRUG
Intervention: Tacrolimus capsule , mycophenolic acid
Description: measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test for study group 1 and study group 2
Study NCT02752282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anticipatory Counseling
Description: Anticipatory Counseling provides information on expected side-effects that may change or go away over time, or stay for the duration of the treatment. Anticipatory counseling can also help patients understand when their side-effects are normal and when to seek medical attention.
Study NCT02752282 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cancer Screening Guidelines
Description: Anticipatory Counseling on United States Preventative Services Task Force (USPSTF) updated pap screening guidelines
Study NCT02356861 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photomedex Sham Helmet with Red/Near-Infrared Light-Emitting Diodes (LEDs) that are not turned on
Description: The LED helmet from Photomedex, Montgomeryville, PA will be used.~18 LED pods are in the helmet. Each LED pod:~Pod size: 19 cm2 Power output: 692.5 mW Power density: 36.5 mW/cm2~20 NIR diodes, 830 nm and 4 red diodes, 633 nm.~1 J/cm2 = 30.4 sec
Study NCT02356861 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Photomedex Sham Helmet with Red/Near-Infrared Light-Emitting Diodes (LEDs) that are not turned on
Description: The LED helmet from Photomedex, Montgomeryville, PA will be used.~18 LED pods are in the helmet. Each LED pod:~Pod size: 19 cm2 Power output: 692.5 mW Power density: 36.5 mW/cm2~20 NIR diodes, 830 nm and 4 red diodes, 633 nm.~1 J/cm2 = 30.4 sec
Study NCT02233361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: A randomized controlled design will determine whether hearing aid users who are informed in advance of a follow-up appointment have a different pattern of hearing aid use than a control group that is not preinformed in advance.
Study NCT04080167 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: InCharge Health mobile application
Description: The InCharge Health app features include: Daily reminders; Ability to customize content of message and time of day when the message comes; Symptom tracker to monitor daily pain and mood; 7-day streak that tracks daily adherence; Graphing adherence against pain symptoms; Communication feature allowing the patient to connect to the clinic and a health partner; Link to discussion forum where communication to other patients can occur; Education bank that provides information about SCD and hydroxyurea. Participants can delay daily push notifications. If hospitalized, participants may stop notifications. A special feature of the app is to set up a health partner, who may be a person the participant may choose from his/her contact list and who will receive notifications if it had been \<4 hours since not documenting the use of hydroxyurea. The app healthy partner will be encouraged to message the participant to remind him/her to take the medication.
Study NCT04080167 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HU Toolbox mobile application
Description: The HU Toolbox app includes algorithms for hydroxyurea use and is ready for immediate use on Apple and Android operating systems. In addition, it has the NHLBI guidelines adapted for pediatrics (guidelines/recommendations separated by age) and for adults (guidelines/ recommendations separated by organ system, laboratory, or physical exam finding). The HU Toolbox app includes the ability to search guidelines for key words and add notes. Algorithms are also included as PDF documents that can be printed out or emailed. Finally, a contact list of local SCD specialists and important contacts is included, so providers can easily contact SCD experts and expect an answer in 24 hours or less. The HU Toolbox app is easily updated with all data and resources stored on a cloud-based server that can provide instant up-to-date information to those using the app.
Study NCT02528812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraBand Roller Massager
Description: The roller massager was moved proximal to distal at a slow pace (2 seconds up and 2 second downs) over the muscle belly. Participants in the Sham group received very light pain-free cutaneous strokes of rolling massage with the same pace of rolling as performed for the Ipsi-R and Contra-R groups. The Control group did not receive any treatment.
Study NCT02528812 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TheraBand Roller Massager
Description: The roller massager was moved proximal to distal at a slow pace (2 seconds up and 2 second downs) over the muscle belly. Participants in the Sham group received very light pain-free cutaneous strokes of rolling massage with the same pace of rolling as performed for the Ipsi-R and Contra-R groups. The Control group did not receive any treatment.
Study NCT02528812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Massage
Description: A massage therapist massaged the participant
Study NCT00111852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmoteplase
Description: Desmoteplase 90 mcg/kg, intravenous administration.
Study NCT00111852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmoteplase
Description: Desmoteplase 125 mcg/kg, intravenous administration.
Study NCT00111852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-Match Placebo, intravenous administration.
Study NCT03339219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib tablets
Study NCT00520806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relaxin
Description: Intravenous infusion for 48 h at 30 ug/kg/day
Study NCT00520806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion for 48 h
Study NCT01526681 — intervention group
Intervention type: OTHER
Intervention: Processed Human Nerve Graft
Description: Implantation of appropriate length of processed human nerve graft at the time of surgery
Study NCT01526681 — intervention group
Intervention type: OTHER
Intervention: Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc.
Description: Historical control from established literature
Study NCT01526681 — intervention group
Intervention type: OTHER
Intervention: Autogenous Nerve Graft
Description: Nerve gap reconstructions with autogenous nerve graft within the upper extremity
Study NCT01526681 — intervention group
Intervention type: DEVICE
Intervention: Nerve Tube Conduit
Description: Nerve gap reconstructions with nerve tube conduit within the upper extremity
Study NCT01526681 — intervention group
Intervention type: PROCEDURE
Intervention: Autologous Breast Reconstruction with Neurotization
Study NCT01526681 — intervention group
Intervention type: PROCEDURE
Intervention: Autologous Breast Reconstruction without Neurotization
Study NCT00629343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine In Combination With Temozolomide
Description: mg, oral
Study NCT04749056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPAS (electronic psycho-oncological adapative screening program)
Description: Adaptive tests assess depression, anxiety and distress. Only items with highest information value are selected. Furthermore, patients fill in a checklist to report supportive care needs.~The results page contains (i) the extent of distress and additional information to interpret these levels, (ii) a summary of the reported supportive care needs and (iii) individualized recommendations for the use of psychosocial services at the institution based on the care needs.~The supportive care needs are transformed into concrete recommendations to use the adequate psychosocial service at the institution. Highly distressed patients are recommended to use psycho-oncological service irrespective of whether they have reported such a need in the check list. Physicians of highly distressed patients are recommended on their results page to talk with the patient about his/her psychosocial condition and further issues within such an appointment are suggested.
Study NCT02858505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 27 mg elemental iron
Study NCT02858505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 54 mg elemental iron
Study NCT01279785 — intervention group
Intervention type: DRUG
Intervention: 123I-MIP-1072
Description: Single IV dose
Study NCT02681978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Ivabradine 5 mg twice daily
Study NCT02681978 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard medical therapy
Description: Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
Study NCT02681978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical therapy
Description: Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
Study NCT00505349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based cognitive training
Description: The experimental cognitive training program consists of interactive training exercises in which the participant responds to visual patterns and stimuli. The program is designed upon the principles of brain-plasticity, and, for the purposes of this study, is intended to be used for an 8-10 week period (40 total hours of training.)
Study NCT03393988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl infusion
Description: After induction of general anesthesia; Fentanyl infusion (0.5 µg/kg/hr) will be started (which will be afterwards adjusted intraoperatively according to the hemodynamics and Bispectral Index (BIS) reading).
Study NCT03393988 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided TAP block
Description: After induction of general anesthesia; Patients will receive ultrasound guided subcostal oblique TAP block with 0.25 % bupivacaine 40 ml on each side resulting in a total volume of 80 ml, subcostal TAP block was given twice, at the beginning and at the end of the surgery.
Study NCT03393988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine (200 µg in 2 ml diluted in 48 ml of saline) will be started in a dose of 1 μg/kg over 10 min then maintenance dose as continuous infusion between 0.2 and 0.8 μg/ kg/h through infusion pump (which will be adjusted according to the hemodynamics and BIS reading)
Study NCT00641368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: R4Power Program
Description: In the 10-lesson online R4Power Program, adolescents will learn cognitive skills (link between thoughts, feelings, and behaviors; thinking traps; challenging negative beliefs) and problem-solving skills (assertiveness; relaxation and distraction; overcoming procrastination; decision-making) in order to cope with stressful situations.
Study NCT00641368 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control
Description: Adolescents in the waitlist control group will complete the R4Power program during the second year of the study.
Study NCT00080236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDN-6556
Study NCT00080236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00080236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT01099332 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gastro-retentive zinc cysteine tablet
Description: Oral, one tablet, once daily with water for 6 months.
Study NCT01099332 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tablet identical physically to active comparator containing some lactose
Description: Oral, once daily, with water, 6 months.
Study NCT00074490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab: 375 mg/m(2)/day intravenous (IV), day 1 (for cluster of differentiation 20 (CD20+) patients).
Study NCT00074490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine: 30 mg/m(2)/day intravenous (IV), days -6 to -3.
Study NCT00074490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide: 50 mg/m(2)/day continuous intravenous (CIV), days 1-4.
Study NCT00074490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin:10 mg/m(2)/day continuous intravenous (CIV), days 1-4.
Study NCT00074490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine: 0.4 mg/m(2)/day continuous intravenous (CIV), days 1-4.
Study NCT00074490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide, 300 mg/m(2)/day intravenous (IV), days -6 to -3.
Study NCT00074490 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell (PBSC) transplantation
Description: PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell.
Study NCT00074490 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells
Description: The dose of the T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) T cells/kg; minimum dose will be 1 x 10(7) T cells/kg).
Study NCT00074490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone: 60 mg/m(2)/day by mouth (PO), days 1-5.
Study NCT00074490 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplant (HSCT)
Description: Allogeneic Hematopoietic Stem Cell Transplant.
Study NCT00074490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim: 5 mcg/kg/day subcutaneous (SC), day 6 (require absolute neutrophil count (ANC) > 1000, two values; or ANC > 5000 cells/ul on one occasion).
Study NCT00074490 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: T-Rapa cell Donor Lymphocyte Infusion (DLI)
Description: The dose of T helper 2 (Th2) cells or unmanipulated donor T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) Th2/kg; minimum dose will be 1 x 10(7) Th2/kg).
Study NCT04141436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventions Based on Hypnofertility
Description: Affirmation Visualization Imagination Relaxation
Study NCT04141436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine clinical procedure
Description: Routine clinical procedure
Study NCT00078897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Selenium
Description: Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.
Study NCT00078897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selenium
Description: Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.
Study NCT01839669 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foot Orthoses Only
Description: patients wear foot orthoses as a treatment condition - no further therapy
Study NCT01839669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Foot Orthoses and Eccentric Exercise
Description: patients wear foot orthoses and they perform an additional home-based eccentric training program for the M. tibialis posterior
Study NCT01839669 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Foot Orthoses
Description: patient wear sham foot orthoses (control condition)
Study NCT03241368 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Capsule Endoscopy
Description: At baseline subject will under the PillCam Crohn's Capsule Procedure
Study NCT01642784 — intervention group
Intervention type: DEVICE
Intervention: Primary PCI of culprit lesion in IRA with drug eluting stent (DES)
Description: Primary PCI of culprit lesion in IRA with drug eluting stent (DES)
Study NCT01642784 — intervention group
Intervention type: DEVICE
Intervention: Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES
Description: Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES
Study NCT02693132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised (SUP-PA)
Description: Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of supervised moderate-to-vigorous intensity physical activity.
Study NCT02693132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unsupervised (UNSUP-PA)
Description: Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of unsupervised moderate-to-vigorous intensity physical activity.
Study NCT02693132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step-based (STEP)
Description: Weight loss intervention that involves an energy restricted diet plus the inclusion of physical activity in the form of 10,000 steps/day with 2,500 brisk steps/day.
Study NCT00453219 — intervention group
Intervention type: PROCEDURE
Intervention: Screening evaluation
Description: A detailed history will be taken and a physical examination performed along with a blood sample to verify ovulatory status in women with regular cycles and determine cause of anovulation in women with irregular or absent menstrual cycles.
Study NCT00453219 — intervention group
Intervention type: PROCEDURE
Intervention: Meal Response
Description: The investigators are interested in how nutrition and metabolism can influence reproduction and they will look at how the body senses hunger and how it responses to food. Blood samples will be collected and questionnaires given to assess responses and feeling about hunger and food.
Study NCT00453219 — intervention group
Intervention type: GENETIC
Intervention: Blood Collection
Description: A blood sample will be collected and used to check for genetic markers of stress vulnerability.
Study NCT00453219 — intervention group
Intervention type: PROCEDURE
Intervention: Functional MRI
Description: research participants will have an functional MRI scan of their brain while reviewing word lists associated with body image and emotions. This procedure will last about 1 hour.
Study NCT00453219 — intervention group
Intervention type: PROCEDURE
Intervention: Endocrine Assessment
Description: research participants will have a 30 hour inpatient hospital admission with every 15 minute blood sampling for 24 hours. Hormone measures of stress, reproduction, and appetite will be obtained.
Study NCT01482052 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: meningococcal meningitis conjugate vaccine, quadrivalent
Description: NmVac4-A/C/Y/W-135-DT™conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 16 µg total diphtheria toxoid.
Study NCT01482052 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: meningococcal meningitis conjugate vaccine, quadrivalent
Description: Meningococcal (Groups A,C,Y and W-135-DT) Polysaccharide Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 48 µg total diphtheria toxoid.
Study NCT01247272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine Hydrochloride
Description: 90 mg Capsules
Study NCT01247272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROZAC WEEKLY®
Description: 90 mg Capsules
Study NCT00405600 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Device used in surgery with or without instrumentation
Description: Infuse Bone Graft BMP-2, Large Kit will be used in all surgeries. Spine surgeries will be either instrumented or uninstrumented.
Study NCT03251313 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: JS001 120mg+GP
Description: In this arm, JS001 120mg will be given at d1; Gem 1000mg/m2 d2,9; DDP(cisplatin) 75mg/m2 d2
Study NCT03251313 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: JS001 240mg+GP
Description: In this arm, JS001 240mg will be given at d1; Gem 1000mg/m2 d2,9; DDP 75mg/m2 d2
Study NCT03251313 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: JS001 480mg+GP
Description: In this arm, JS001 480mg will be given at d1; Gem 1000mg/m2 d2,9; DDP 75mg/m2 d2
Study NCT03251313 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: GP followed by JS001
Description: In this arm,Patients receive 6 cycles of GP without JS001 and then receive JS001 maintenance therapy for up to approximately 2 years. JS001 will be given at RP2D.
Study NCT01032252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: 16 week exercise once a week of 60 minutes intervention by trained fall prevention instructors and a home program.~Intervention includes strength/power training, balance/gait training, behavioral aspects and perceptual and functional training.
Study NCT04150861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin Delta
Description: Solution for Injection, subcutaneous administration